Immunome Shares Are Trading Higher After the Company Announced That It Entered Into a Definitive Asset Purchase Agreement With Ayala Pharmaceuticals to Acquire AL102 and AL101 Drug Candidates
Immunome宣布与阿亚拉制药公司签订最终资产购买协议以收购 AL102 和 AL101 候选药物后，该公司股价走高